Week in Review: Beijing Genomics Institute (BGI) Shenzhen Planning Partial IPO

by Richard Daverman, PhD

September 7, 2013 --BGI Shenzhen, the giant sequencing company, is planning to split itself in two and IPO its institutional sequencing business, though the company has yet to make an official announcement; Acebright Holdings of China will make a $1 million investment in NasVax, an Israeli immunotherapy company, and signed an MOU to develop NasVax's treatment for fatty liver disease in China and India; Eddingpharm in-licensed China rights to a clinical-stage cancer treatment from Syndax Pharma of Massachusetts; Hua Medicine began a China Phase I clinical trial of a novel Glucokinase activator treatment for diabetes 2 that was in-licensed from Roche; and China’s Ministry of Public Security said GlaxoSmithKline deserved an “astronomical fine” for bribing China doctors and officials. More details….

Stock Symbols: (TASE: NSVX) (SX: ROG) (NYSE: GSK)

Help employers find you! Check out all the jobs and post your resume.